Patents Represented by Attorney Gregory W. Steele

Find this attorney in the Justia Lawyer Directory

  • Ureas having antiangiogenic activity
    Patent number: 7592466
    Abstract: Compounds having the formula are angiogenesis inhibitors. Also disclosed are compositions containing the compounds, methods of making the compounds, and methods of treatment using the compounds.
    Type: Grant
    Filed: October 8, 2004
    Date of Patent: September 22, 2009
    Assignee: Abbott Laboratories
    Inventors: Fortuna Haviv, Michael F. Bradley, Daryl R. Sauer
  • 1H-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent PARP inhibitors
    Patent number: 7550603
    Abstract: Compounds of Formula (I) inhibit the PARP enzyme and are useful for treating a disease or a disorder associated with PARP. Also disclosed are pharmaceutical compositions comprising compounds of Formula (I), methods of treatment comprising compounds of Formula (I), and methods of inhibiting the PARP enzyme comprising compounds of Formula (I).
    Type: Grant
    Filed: April 11, 2006
    Date of Patent: June 23, 2009
    Assignee: Abbott Laboratories Inc.
    Inventors: Gui-Dong Zhu, Jianchun Gong, Virajkumar B. Gandhi, Thomas D. Penning, Vincent L. Giranda
  • Salts of fenofibric acid and pharmaceutical formulations thereof
    Patent number: 7259186
    Abstract: In one aspect, the present invention relates to a formulation in the form of molecular dispersion comprising i) fenofibric acid, a physiologically acceptable salt or derivative thereof and optionally other active substances, ii) a binder component comprising at least one enteric binder, and optionally iii) other physiologically acceptable excipients. In a second aspect, the present invention relates to novel salts of fenofibric acid that are photostable when compared to other salts of fenofibric acid.
    Type: Grant
    Filed: June 30, 2004
    Date of Patent: August 21, 2007
    Assignee: Abbott Laboratories
    Inventors: Russell Drew Cink, Joseph B. Paterson, Jr., Yi Gao, Geoff G. Z. Zhang, Michelle A. Long, John B. Morris, Joerg Rosenberg
  • Formulations comprising lipid-regulating agents
    Patent number: 7014864
    Abstract: The present invention is directed to a formulation comprising a lipid-regulating agent dissolved in at least one structured lipid as the primary solvent medium for said agent. One or more emulsifiers may be added to the formulation.
    Type: Grant
    Filed: December 18, 1998
    Date of Patent: March 21, 2006
    Assignee: Abbott Laboratories
    Inventors: John M. Lipari, Dawn M. Raymond, Tom Reiland
  • Formulations comprising lipid-regulating agents
    Patent number: 6838091
    Abstract: The present invention is directed to a formulation comprising a lipid-regulating agent dissolved in at least one monoglyceride as the primary solvent medium for said agent. One or more emulsifiers may be added to the formulation.
    Type: Grant
    Filed: December 18, 1998
    Date of Patent: January 4, 2005
    Assignee: Abbott Laboratories
    Inventors: John M. Lipari, Dawn M. Raymond, Tom Reiland, Yeshwant D. Sanzgiri
  • Kinase inhibitors
    Patent number: 6831175
    Abstract: Compounds having the formula are useful for inhibiting protein kinases. Also disclosed are compositions which inhibit protein kinases and methods of inhibiting protein kinases in a patient.
    Type: Grant
    Filed: December 12, 2002
    Date of Patent: December 14, 2004
    Assignee: Abbott Laboratories
    Inventors: Qun Li, Keith W. Woods, Gui-Dong Zhu, John P. Fischer, Jianchun Gong, Tongmei Li, Virajkumar Gandhi, Sheela A. Thomas, Garrick K. Packard, Xiaohong Song, Jason N. Abrams, Robert B. Diebold, Jürgen Dinges, Charles W. Hutchins, Vincent S. Stoll, Saul H. Rosenberg, Vincent L. Giranda
  • Formulations comprising lipid-regulating agents
    Patent number: 6814977
    Abstract: The present invention is directed to a formulation comprising a lipid-regulating agent dissolved in at least one medium chain glycerol ester of a fatty acid as the primary solvent medium for said agent. One or more emulsifiers may be added to the formulation.
    Type: Grant
    Filed: December 18, 1998
    Date of Patent: November 9, 2004
    Assignee: Abbott Laboratories
    Inventors: John M. Lipari, Dawn M. Raymond, Tom Reiland
  • Protein kinase inhibitors
    Patent number: 6797825
    Abstract: Compounds having the formula or therapeutically acceptable salts thereof, are protein kinase inhibitors. Preparation of the compounds, compositions containing the compounds, and treatment of diseases using the compounds are disclosed.
    Type: Grant
    Filed: December 12, 2002
    Date of Patent: September 28, 2004
    Assignee: Abbott Laboratories
    Inventors: Nan-Horng Lin, Hing L. Sham, Ping Xia
  • N-alkylated peptides having antiangiogenic activity
    Patent number: 6777535
    Abstract: N-Alkylated peptides of formula (I) Xaa1-Xaa2-Xaa3-Xaa4-Xaa5-Xaa6-Xaa7-Xaa8-Xaa9-Xaa10-Xaa11  (I), are useful for inhibiting angiogenesis. Also disclosed are angiogenesis-inhibiting compositions and methods of inhibiting angiogenesis in a mammal.
    Type: Grant
    Filed: October 31, 2000
    Date of Patent: August 17, 2004
    Assignee: Abbott Laboratories
    Inventors: Fortuna Haviv, Jack Henkin, Douglas M. Kalvin, Michael F. Bradley
  • Peptide antiangiogenic drugs
    Patent number: 6774211
    Abstract: Peptides having the formula: A0-A1-A2-A3-A4-A5-A6-A7-A8-A9-A10 wherein A0 is selected from hydrogen or an acyl group; A10 is a hydroxyl group or an amino acid amide; and A1, A2, A3, A4, A5, A6, A7, A8, and A9 are amino acyl residues as defined herein.
    Type: Grant
    Filed: April 11, 2001
    Date of Patent: August 10, 2004
    Assignee: Abbott Laboratories
    Inventors: Jack Henkin, Fortuna Haviv, Michael F. Bradley, Douglas M. Kalvin, Andrew J. Schneider
  • Preparation of K-252a
    Patent number: 6723844
    Abstract: The present invention provides a process for the synthesis of K-252a and intermediates useful in the process.
    Type: Grant
    Filed: February 27, 2003
    Date of Patent: April 20, 2004
    Assignee: Abbott Laboratories
    Inventors: Navayath Shobana, John C. Strong, Mark W. Tubergen, Russell A. Brierley
  • N-acylsulfonamide apoptosis promoters
    Patent number: 6720338
    Abstract: N-Benzoyl arylsulfonamides having the formula: are BCL-X1 inhibitors and are useful for promoting apoptosis. Also disclosed are BCL-X1 inhibiting compositions and methods of promoting apoptosis in a mammal.
    Type: Grant
    Filed: September 20, 2001
    Date of Patent: April 13, 2004
    Assignee: Abbott Laboratories
    Inventors: David J. Augeri, Steven A. Baumeister, Milan Bruncko, Daniel A. Dickman, Hong Ding, Jurgen Dinges, Stephen W. Fesik, Philip J. Hajduk, Aaron R. Kunzer, William McClellan, David G. Nettesheim, Thorsten Oost, Andrew M. Petros, Saul H. Rosenberg, Wang Shen, Sheela A. Thomas, Xilu Wang, Michael D. Wendt
  • Peptide antiangiogenic drugs
    Patent number: 6716963
    Abstract: Peptides having the formula: A0-A1-A2-A3-A4-A5-A6-A7-A8-A9-A10 wherein A0 is selected from hydrogen or an acyl group; A10 is a hydroxyl group or an amino acid amide; and A1, A2, A3, A4, A5, A6, A7, A8, and A9 are amino acyl residues as defined herein.
    Type: Grant
    Filed: November 22, 1999
    Date of Patent: April 6, 2004
    Assignee: Abbott Laboratories
    Inventors: Jack Henkin, Fortuna Haviv, Michael F. Bradley, Douglas M. Kalvin, Andrew J. Schneider
  • Process for the preparation of cell proliferation inhibitors
    Patent number: 6710185
    Abstract: The instant invention discloses a process for the synthesis of substituted indole cell proliferation inhibitors.
    Type: Grant
    Filed: September 20, 2001
    Date of Patent: March 23, 2004
    Assignee: Abbott Laboratories
    Inventors: Ashok K. Gupta, Steven A. King, Elaine C. Lee, Howard E. Morton, Daniel J. Plata, Yu-Ming Pu, Padam N. Sharma
  • Antiangiogenic peptides
    Patent number: 6699838
    Abstract: Mammalian kringle 5 fragments and kringle 5 fusion proteins are disclosed as a compounds for treating angiogenic diseases. Methods and compositions for inhibiting angiogenic diseases are also disclosed.
    Type: Grant
    Filed: September 5, 1997
    Date of Patent: March 2, 2004
    Assignee: Abbott Laboratories
    Inventor: Donald J. Davidson
  • Antiangiogenic drug to treat cancer, arthritis and retinopathy
    Patent number: 6632961
    Abstract: Compounds having Formula I or pharmaceutically acceptable salts or prodrugs thereof, are useful for treating pathological states which arise from or are exacerbated by angiogenesis. The invention also relates to pharmaceutical compositions comprising these compounds and to methods of inhibiting angiogenesis in a mammal.
    Type: Grant
    Filed: May 21, 1999
    Date of Patent: October 14, 2003
    Assignee: Abbott Laboratories
    Inventors: Megumi Kawai, Jack Henkin, George S. Sheppard, Richard A. Craig
  • Naphthamidine urokinase inhibitors
    Patent number: 6495562
    Abstract: Compounds having the formula are inhibitors of urokinase and are useful in the treatment of diseases in which urokinase plays a role. Also disclosed are urokinase-inhibiting compositions, methods for the preparation of urokinase-inhibitors, and a method of inhibiting urokinase in a mammal.
    Type: Grant
    Filed: April 25, 2001
    Date of Patent: December 17, 2002
    Assignee: Abbott Laboratories
    Inventors: Milan Bruncko, Christopher Robin Dalton, Vincent Louis Giranda, Jianchun Gong, Willian J. McClellan, Vicki L. Nienaber, Todd Warren Rockway, Daryl Richard Sauer, Moshe Weitzberg
  • Process for the preparation of matrix metalloproteinase inhibitors
    Patent number: 6441189
    Abstract: The instant invention provides a process for the synthesis of matrix metalloproteinase inhibitors.
    Type: Grant
    Filed: December 13, 2001
    Date of Patent: August 27, 2002
    Assignee: Abbott Laboratories
    Inventors: Anne E. Bailey, David R. Hill, Chi-nung W. Hsiao, Ravi Kurukulasuriya, Steve Wittenberger, Todd McDermott, Maureen A. McLaughlin
  • Process for the selective N-formylation of N-hydroxylamines
    Patent number: 6350902
    Abstract: The instant invention provides a process for the selective N-formylation of N-hydroxylamines.
    Type: Grant
    Filed: March 30, 2001
    Date of Patent: February 26, 2002
    Assignee: Abbott Laboratories
    Inventors: David R. Hill, Chi-Nung Hsiao, Ravi Kurukulasuriya, Steve Wittenberger
  • Reverse hydroxamate inhibitors of matrix metalloproteinases
    Patent number: 6294573
    Abstract: Compounds having the formula are matrix metalloproteinase inhibitors. Also disclosed are matrix metalloproteinase-inhibiting compositions and methods of inhibiting matrix metalloproteinase in a mammal.
    Type: Grant
    Filed: January 27, 2000
    Date of Patent: September 25, 2001
    Assignee: Abbott Laboratories
    Inventors: Michael L. Curtin, Yujia Dai, Steven K. Davidsen, Joseph F. Dellaria, Jr., Alan S. Florjancic, Jianchun Gong, Yan Guo, Howard R. Heyman, James H. Holms, Michael R. Michaelides, Jamie R. Stacey, Douglas H. Steinman, Carol K. Wada, Lianhong Xu